Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from PYC Therapeutics Limited ( (AU:PYC) ).
PYC Therapeutics Limited has launched a pro-rata non-renounceable entitlement offer, allowing eligible shareholders in Australia, New Zealand and certain other jurisdictions to subscribe for three new fully paid ordinary shares for every five shares held as at 4.00pm (Perth time) on 4 February 2026. The offer will be conducted without a disclosure document under Part 6D.2 of the Corporations Act, with the company confirming ongoing compliance with its financial reporting and continuous disclosure obligations, stating there is no excluded information to disclose and indicating that the new share issue is not expected to materially affect control of the company, thereby limiting potential dilutionary or governance impacts for existing shareholders.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an Australian biotechnology company listed on the ASX, focused on developing therapeutics, with its shareholder base primarily in Australia, New Zealand and select international jurisdictions where its securities are offered and traded.
Average Trading Volume: 477,141
Technical Sentiment Signal: Buy
Current Market Cap: A$933.2M
See more insights into PYC stock on TipRanks’ Stock Analysis page.